# The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer

> **NCT01739634** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Salient Pharmaceuticals Incorporated** · enrollment: 10 (estimated)

## Conditions studied

- Diarrhea
- Medullary Thyroid Cancer

## Interventions

- **DRUG:** CASAD

## Key facts

- **NCT ID:** NCT01739634
- **Lead sponsor:** Salient Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-11
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2012-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01739634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01739634, "The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01739634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*